Suvasini Lakshmanan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Suvasini Lakshmanan has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Jay Budoff
Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California, USA
4 shared publications - April Kinninger
The Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, 1124 W Carson St, Torrance, CA 90502, USA
3 shared publications - Sion K. Roy
Division of Cardiology, Harbor–UCLA Medical Center and Lundquist Institute for Biomedical Innovation, Torrance, USA
3 shared publications - Srikanth Krishnan
Harbor-UCLA Medical Center and The Lundquist Institute for Biomedical Innovation at Harbor-UCLA
3 shared publications - Beshoy Iskander
Division of Cardiology, Harbor–UCLA Medical Center and Lundquist Institute for Biomedical Innovation, Torrance, USA
2 shared publications - Keishi Ichikawa
Lundquist Institute, Harbor-UCLA Medical Center, Torrance, USA
2 shared publications
Latest Publications
- 19 January 2026
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 42 (5) , 819-824
Symptom status and non-calcified plaque burden across CAC strata: insights from AI-based CCTA quantification
To investigate whether non-calcified coronary plaque (NCP) volume differs between symptomatic versus asymptomatic individuals across strata of coronary artery calcium (CAC) score, and whether symptom status adds incremental value beyond CAC. In this retrospective single-center study, we analyzed 1,835 adults (14% symptomatic, 86% asymptomatic) who underwent coronary CT angiography (CCTA) with AI-based plaque quantification. Participants were stratified into five CAC categories: 0, 1–99, 100–299, 300–1000, and > 1000 Agatston units. Total NCP volume was compared between symptomatic and asymptomatic patients within each stratum using non-parametric tests. Median NCP volumes were similar in both groups for CAC 0 (17.7 vs. 18.6 mm³, p = 0.96) and CAC 1–99 (50.8 vs. 56.3 mm³, p = 0.37). A significant difference emerged in the CAC 100–299 category: symptomatic patients had higher NCP (152.3 vs. 112.3 mm³, p = 0.035). No significant differences were seen in CAC 300–1000 or > 1000 (p = 0.12 and p = 0.066, respectively). Symptom status may be associated with higher non-calcified plaque burden particularly in symptomatic patients with CAC 100–299. Prospective outcome studies are needed to determine whether AI-quantified NCP volume can guide preventive therapy independent of CAC.
- 19 January 2026
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 42 (5) , 819-824
Symptom status and non-calcified plaque burden across CAC strata: insights from AI-based CCTA quantification
To investigate whether non-calcified coronary plaque (NCP) volume differs between symptomatic versus asymptomatic individuals across strata of coronary artery calcium (CAC) score, and whether symptom status adds incremental value beyond CAC. In this retrospective single-center study, we analyzed 1,835 adults (14% symptomatic, 86% asymptomatic) who underwent coronary CT angiography (CCTA) with AI-based plaque quantification. Participants were stratified into five CAC categories: 0, 1–99, 100–299, 300–1000, and > 1000 Agatston units. Total NCP volume was compared between symptomatic and asymptomatic patients within each stratum using non-parametric tests. Median NCP volumes were similar in both groups for CAC 0 (17.7 vs. 18.6 mm³, p = 0.96) and CAC 1–99 (50.8 vs. 56.3 mm³, p = 0.37). A significant difference emerged in the CAC 100–299 category: symptomatic patients had higher NCP (152.3 vs. 112.3 mm³, p = 0.035). No significant differences were seen in CAC 300–1000 or > 1000 (p = 0.12 and p = 0.066, respectively). Symptom status may be associated with higher non-calcified plaque burden particularly in symptomatic patients with CAC 100–299. Prospective outcome studies are needed to determine whether AI-quantified NCP volume can guide preventive therapy independent of CAC.
- Open Access
- 26 September 2025
- Published by MDPI AG in Cardiogenetics
- Vol. 15 (4) , 27
Polygenic Risk Scores and Coronary Artery Disease
Background: Polygenic risk scores (PRSs) aggregate the effects of many common genetic variants and are being investigated as tools to refine coronary artery disease (CAD) risk prediction beyond traditional clinical models. Methods and Results: We review the development of PRS from early unweighted scores to contemporary genome-wide models and summarize evidence from major studies. We identified key studies through PubMed searches using the terms “polygenic risk score,” “genetic risk prediction,” and “coronary artery disease,” supplemented by citation chaining of highly cited articles and recent reviews. Large cohorts, such as the UK Biobank, show that individuals in the highest PRS percentiles have a 3–5-fold higher risk of CAD, and may gain the greatest benefit from statin therapy. PRS can also reclassify younger adults at borderline or intermediate risk and may complement coronary artery calcium (CAC) scoring. Conclusions: PRSs hold promise for lifetime risk stratification and targeted prevention in CAD but are limited by ancestry bias in GWAS, underrepresentation of diverse populations, inconsistency in individual estimates, and lack of standardized reporting. Future research should focus on expanding multi-ancestry databases, standardizing methods, prospective validation, and effective communication strategies to support equitable and evidence-based clinical use.
- 26 September 2025
- Published by MDPI AG in Cardiogenetics
- Vol. 15 (4) , 27
Open AccessPolygenic Risk Scores and Coronary Artery Disease
Background: Polygenic risk scores (PRSs) aggregate the effects of many common genetic variants and are being investigated as tools to refine coronary artery disease (CAD) risk prediction beyond traditional clinical models. Methods and Results: We review the development of PRS from early unweighted scores to contemporary genome-wide models and summarize evidence from major studies. We identified key studies through PubMed searches using the terms “polygenic risk score,” “genetic risk prediction,” and “coronary artery disease,” supplemented by citation chaining of highly cited articles and recent reviews. Large cohorts, such as the UK Biobank, show that individuals in the highest PRS percentiles have a 3–5-fold higher risk of CAD, and may gain the greatest benefit from statin therapy. PRS can also reclassify younger adults at borderline or intermediate risk and may complement coronary artery calcium (CAC) scoring. Conclusions: PRSs hold promise for lifetime risk stratification and targeted prevention in CAD but are limited by ancestry bias in GWAS, underrepresentation of diverse populations, inconsistency in individual estimates, and lack of standardized reporting. Future research should focus on expanding multi-ancestry databases, standardizing methods, prospective validation, and effective communication strategies to support equitable and evidence-based clinical use.
- Open Access
- 22 September 2025
- Published by MDPI AG in Emergency Care and Medicine
- Vol. 2 (3) , 46
Coronary CT Angiography for Acute Chest Pain in the Emergency Department: A Systematic Review of Clinical Utility
Introduction: Chest pain is one of the most common and high-risk presentations in the emergency department (ED), necessitating timely and accurate evaluation to prevent adverse cardiovascular outcomes. Coronary Computed Tomography Angiography (CCTA) has emerged as a promising non-invasive modality with high sensitivity (90–100%) and a negative predictive value (98–100%) for ruling out significant coronary artery disease (CAD), as evidenced by trials such as ROMICAT II and ACRIN-PA. Despite its expanding role in ED triage, further evaluation of its impact on patient-centered outcomes is essential. Methods: A systematic review was conducted in accordance with PRISMA guidelines. Studies published between January 2010 and June 2025 were identified from PubMed, Embase, and the Cochrane Library. Eligible studies included randomized controlled trials and prospective cohort studies assessing CCTA in ED patients with suspected acute coronary syndrome (ACS), compared with alternative diagnostic strategies, and reporting outcomes, including diagnostic accuracy, time to diagnosis, ED discharge rates, hospital admissions, and cost-effectiveness. Results: Twenty-three studies comprising over 60,000 patients were included. CCTA in low- to intermediate-risk patients significantly reduced diagnostic time (up to 54%), increased early ED discharges, and lowered unnecessary admissions. It consistently demonstrated excellent diagnostic performance, with pooled sensitivity ≥90% and near-perfect negative predictive value. Economic evaluations showed reduced costs due to shorter ED stays and less downstream testing. Challenges included radiation exposure, contrast use, and incidental findings. Conclusions: CCTA enhances ED efficiency and safety in ACS evaluation, offering accurate CAD exclusion and resource optimization. Future studies should explore its long-term cost-effectiveness and integration into high-sensitivity troponin protocols.
- 22 September 2025
- Published by MDPI AG in Emergency Care and Medicine
- Vol. 2 (3) , 46
Open AccessCoronary CT Angiography for Acute Chest Pain in the Emergency Department: A Systematic Review of Clinical Utility
Introduction: Chest pain is one of the most common and high-risk presentations in the emergency department (ED), necessitating timely and accurate evaluation to prevent adverse cardiovascular outcomes. Coronary Computed Tomography Angiography (CCTA) has emerged as a promising non-invasive modality with high sensitivity (90–100%) and a negative predictive value (98–100%) for ruling out significant coronary artery disease (CAD), as evidenced by trials such as ROMICAT II and ACRIN-PA. Despite its expanding role in ED triage, further evaluation of its impact on patient-centered outcomes is essential. Methods: A systematic review was conducted in accordance with PRISMA guidelines. Studies published between January 2010 and June 2025 were identified from PubMed, Embase, and the Cochrane Library. Eligible studies included randomized controlled trials and prospective cohort studies assessing CCTA in ED patients with suspected acute coronary syndrome (ACS), compared with alternative diagnostic strategies, and reporting outcomes, including diagnostic accuracy, time to diagnosis, ED discharge rates, hospital admissions, and cost-effectiveness. Results: Twenty-three studies comprising over 60,000 patients were included. CCTA in low- to intermediate-risk patients significantly reduced diagnostic time (up to 54%), increased early ED discharges, and lowered unnecessary admissions. It consistently demonstrated excellent diagnostic performance, with pooled sensitivity ≥90% and near-perfect negative predictive value. Economic evaluations showed reduced costs due to shorter ED stays and less downstream testing. Challenges included radiation exposure, contrast use, and incidental findings. Conclusions: CCTA enhances ED efficiency and safety in ACS evaluation, offering accurate CAD exclusion and resource optimization. Future studies should explore its long-term cost-effectiveness and integration into high-sensitivity troponin protocols.
- Open Access
- 15 September 2025
- Published by Springer Nature in Nature Reviews Cardiology
- p. 1-2
Rethinking the mentoring paradigm to include mentor, sponsor and advocate
- 15 September 2025
- Published by Springer Nature in Nature Reviews Cardiology
- p. 1-2
Open AccessRethinking the mentoring paradigm to include mentor, sponsor and advocate
- 1 April 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (4) , 490-491
Racial differences in atherosclerosis and coronary plaque characteristics using enhanced AI quantification (RACE-AI)
- 1 April 2025
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 19 (4) , 490-491
Racial differences in atherosclerosis and coronary plaque characteristics using enhanced AI quantification (RACE-AI)
- Open Access
- 1 January 2022
- Published by Touch Medical Media, Ltd. in Heart International
- Vol. 16 (1) , 2-11
Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden
Treatment of established risk factors, especially low-density lipoprotein (LDL) cholesterol, is the cornerstone of preventing atherosclerotic coronary artery disease. Despite reducing LDL cholesterol, there remains a significant risk of cardiovascular disease. Inflammatory and metabolic pathways contribute to recurrence of cardiovascular events, and are often missed in clinical practice. Eicosapentaenoic acid (EPA) may play a crucial role in reducing residual risk of cardiovascular disease. In this review we discuss the clinical applications of omega-3 fatty acids (OM3FAs), their mechanism of action, the difference between pure EPA and docosahexaenoic acid components, and the latest cardiovascular outcome trials and imaging trials evaluating coronary plaque. PubMed and EMBASE were searched to include all the remarkable clinical trials investigating OM3FAs and cardiovascular disease. Beyond statins, additional medications are required to reduce the risk of cardiovascular disease. EPA has shown cardiovascular benefit in addition to statins in large outcome trials. Additionally, multiple serial-imaging studies have demonstrated benefits on plaque progression and stabilization. Due to its pleotropic properties, icosapent ethyl outperforms other OM3FAs in decreasing cardiovascular disease risk in both patients with and without high triglycerides, and is currently recommended as an adjunct to statins. To further strengthen the current evidence, additional research is required to elucidate the inconsistencies between the effects of pure EPA and EPA plus docosahexaenoic acid.
- 1 January 2022
- Published by Touch Medical Media, Ltd. in Heart International
- Vol. 16 (1) , 2-11
Open AccessMultimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden
Treatment of established risk factors, especially low-density lipoprotein (LDL) cholesterol, is the cornerstone of preventing atherosclerotic coronary artery disease. Despite reducing LDL cholesterol, there remains a significant risk of cardiovascular disease. Inflammatory and metabolic pathways contribute to recurrence of cardiovascular events, and are often missed in clinical practice. Eicosapentaenoic acid (EPA) may play a crucial role in reducing residual risk of cardiovascular disease. In this review we discuss the clinical applications of omega-3 fatty acids (OM3FAs), their mechanism of action, the difference between pure EPA and docosahexaenoic acid components, and the latest cardiovascular outcome trials and imaging trials evaluating coronary plaque. PubMed and EMBASE were searched to include all the remarkable clinical trials investigating OM3FAs and cardiovascular disease. Beyond statins, additional medications are required to reduce the risk of cardiovascular disease. EPA has shown cardiovascular benefit in addition to statins in large outcome trials. Additionally, multiple serial-imaging studies have demonstrated benefits on plaque progression and stabilization. Due to its pleotropic properties, icosapent ethyl outperforms other OM3FAs in decreasing cardiovascular disease risk in both patients with and without high triglycerides, and is currently recommended as an adjunct to statins. To further strengthen the current evidence, additional research is required to elucidate the inconsistencies between the effects of pure EPA and EPA plus docosahexaenoic acid.
- Open Access
- 15 July 2021
- Published by Touch Medical Media, Ltd. in Heart International
- Vol. 15 (1) , 7-13
The Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?
There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies for
- 15 July 2021
- Published by Touch Medical Media, Ltd. in Heart International
- Vol. 15 (1) , 7-13
Open AccessThe Evolving Role of Omega 3 Fatty Acids in Cardiovascular Disease: Is Icosapent Ethyl the Answer?
There are several beneficial effects of statins on the progression of atherosclerosis, and there have been significant advancements in pharmacotherapies for
- 1 June 2020
- Published by Elsevier in Atherosclerosis
- Vol. 302, 15-19
Association of flow mediated vasodilation and burden of subclinical atherosclerosis by coronary CTA
- 1 June 2020
- Published by Elsevier in Atherosclerosis
- Vol. 302, 15-19
Association of flow mediated vasodilation and burden of subclinical atherosclerosis by coronary CTA